WINDLASPharmaceuticals
Windlas Biotech Ltd — PE Ratio & Valuation Analysis
₹736.75
-1.94%
Current P/E24.62xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E25.0x1.6% below avg
✅
22.5% Discount to Industry
WINDLAS P/E 24.62x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹28.87 | ₹795 | 27.5x |
| 2024 | ₹27.88 | ₹1041 | 37.3x |
| 2023 | ₹19.70 | ₹429 | 21.8x |
| 2022 | ₹18.58 | ₹250 | 13.5x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Windlas Biotech Ltd Valuation
Windlas Biotech Ltd (WINDLAS) currently trades at 24.62x earnings. The Pharmaceuticals sector average PE is 31.77x. WINDLAS is trading at a discount to peers — may indicate relative value. Historically, WINDLAS has traded at an average PE of 25.0x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
12.76%
Dividend Yield
0.74%
More on Windlas Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.